Company
Steminov
- Business model
- B2B
Claim, correct or request removal
Record updated 28 September 2026
About
Who we are StemInov Innovation A new Mesenchymal Stromal Cells (MSC) platform overcoming current cell therapy limitations and addressing strong unmet medical needs The platform → Excellent efficacy and safety in preclinical studies Preclinical results → Entry of phase IIa in severe Community Aquired Pneumonia (CPA) Clinical development → Blockbuster potential in Community Acquired Pneumonia (CAP) associated with […]
Loading relationship preview